hVIVO plc (LON:HVO - Get Free Report)'s share price traded down 46.3% during trading on Friday . The company traded as low as GBX 6.50 ($0.09) and last traded at GBX 8.70 ($0.12). 83,062,000 shares were traded during trading, an increase of 2,325% from the average session volume of 3,424,608 shares. The stock had previously closed at GBX 16.20 ($0.22).
Analyst Upgrades and Downgrades
Separately, Shore Capital reaffirmed a "buy" rating on shares of hVIVO in a report on Friday.
Read Our Latest Analysis on hVIVO
hVIVO Price Performance
The company has a quick ratio of 1.16, a current ratio of 1.61 and a debt-to-equity ratio of 33.86. The company has a market cap of £61.56 million, a price-to-earnings ratio of 3.59 and a beta of 0.97. The company has a fifty day simple moving average of GBX 16.16 and a two-hundred day simple moving average of GBX 18.13.
hVIVO (LON:HVO - Get Free Report) last released its quarterly earnings results on Thursday, April 10th. The company reported GBX 1.69 ($0.02) EPS for the quarter. hVIVO had a return on equity of 47.93% and a net margin of 25.96%. On average, equities research analysts anticipate that hVIVO plc will post 1.5492958 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other hVIVO news, insider Yamin Mo' Khan sold 3,062,246 shares of the company's stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of GBX 17 ($0.23), for a total value of £520,581.82 ($700,459.93). 14.03% of the stock is currently owned by insiders.
hVIVO Company Profile
(
Get Free Report)
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.
Further Reading
Before you consider hVIVO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and hVIVO wasn't on the list.
While hVIVO currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
